Medivolve Inc. MEDVF
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -91.11% | -97.49% | -98.95% | -99.08% | -89.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -91.11% | -97.49% | -98.95% | -99.08% | -89.51% |
| Cost of Revenue | -100.91% | -100.25% | -100.20% | -100.01% | -89.80% |
| Gross Profit | -80.08% | -93.66% | -97.61% | -98.00% | -89.16% |
| SG&A Expenses | -71.47% | -78.04% | -77.25% | -78.29% | -24.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -78.07% | -86.58% | -90.10% | -91.81% | -68.99% |
| Operating Income | 68.50% | 65.21% | -206.51% | -144.22% | -171.20% |
| Income Before Tax | 75.32% | 69.02% | -567.50% | -190.07% | -276.69% |
| Income Tax Expenses | -- | -- | -- | -- | -154.97% |
| Earnings from Continuing Operations | 67.46% | 59.58% | -58.07% | -244.66% | -698.95% |
| Earnings from Discontinued Operations | -31.99% | -71.35% | -10.09% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.09% | 13.59% | -30.30% | -398.77% | -1,096.16% |
| EBIT | 68.50% | 65.21% | -206.51% | -144.22% | -171.20% |
| EBITDA | 68.00% | 65.43% | -179.54% | -131.90% | -151.66% |
| EPS Basic | 29.09% | 13.59% | -26.38% | -382.98% | -193.13% |
| Normalized Basic EPS | 70.13% | 66.85% | -264.46% | -151.92% | -203.53% |
| EPS Diluted | 28.62% | 12.92% | -27.72% | -383.31% | -193.40% |
| Normalized Diluted EPS | 70.13% | 66.85% | -264.46% | -151.92% | -203.53% |
| Average Basic Shares Outstanding | 0.01% | 0.01% | -1.30% | 0.53% | 14.76% |
| Average Diluted Shares Outstanding | 0.01% | 0.01% | -1.30% | 0.53% | 14.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |